- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01304654
ALI (Acute Lung Injury) /ARDS (Acute Respiratory Distress Syndrome) in Oncologic Pediatric Patients
Practice of Mechanical Ventilation in Pediatric Oncologic Patients Diagnosed with Acute Lung Injury / Acute Respiratory Distress Syndrome
Study Overview
Status
Detailed Description
Evaluate adequate mechanical ventilation based on protective ventilation protocols for children available so far.
Evaluate and describe the subjects. Evaluate the necessity and outcome of rescue therapies (surfactant, prone position, corticosteroids, alveolar recruitment) Obtain data about ALI/ARDS' etiology, mortality rates and predictive factors related to the outcomes (PICU/ hospital discharge or death)
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Sao Paulo, Brazil, 04023-062
- Grupo de Apoio ao Adolescente e à Criança com Câncer
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients admitted at the intensive care unit with diagnosis of acute lung injury or acute respiratory distress syndrome and submitted to mechanical ventilation for over 24h
Exclusion Criteria:
- mechanical ventilation less than 24h
- absence of ALI/ARDS criteria
- no neoplasm diagnosis
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
ALI/ARDS oncologic patients
Consecutively admitted patients at GRAACC's PICU with malignancy diagnosis according to IDC-10, in a 24mo consecutive period, under mechanical ventilation for over 24h and with ALI/ARDS criteria, not younger than 29 days or older than 17 years 11 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Identify pediatric oncologic patients with ALI/ARDS at GRAACC's PICU and evaluate how they are mechanically ventilated
Time Frame: 2y
|
2y
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Epidemiologic data about the selected patients
Time Frame: 28 days
|
Type and data about their mechanical ventilation, etiologic factors for ALI/ARDS, mortality rates, predictive factors about outcomes (death/ discharge), necessity and types of rescue therapies (surfactant, prone position, corticosteroids, etc.)
|
28 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Rodrigo G Arduini, MD, Grupo de Apoio ao Adolescente e à Criança com Câncer
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UTI/IOP 02/11
- 0031/11 (Other Identifier: CEP UNIFESP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
Peking University First HospitalRecruitingBreast Neoplasms、Lung Neoplasms、Pancreatic NeoplasmsChina
-
Hospices Civils de LyonNot yet recruiting
-
GlaxoSmithKlineCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Recruiting
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ain Shams UniversityNot yet recruiting
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
Medical College of WisconsinM.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Chicago and other collaboratorsRecruiting
-
GlaxoSmithKlineRecruitingNeoplasms, ColonSpain, Belgium, Japan, Italy, United Kingdom, Switzerland